Ignite Creation Date:
2025-12-24 @ 4:49 PM
Ignite Modification Date:
2026-02-07 @ 8:10 AM
Study NCT ID:
NCT04195750
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-04-29
First Post:
2019-12-10
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Carcinoma, Renal Cell | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Hypoxia inducible Factor (HIF) | View |
| None | Hypoxia inducible factor 1B (HIF-1B) | View |
| None | Hypoxia inducible factor 2 alpha (HIF-2 alpha) | View |
| None | Hypoxia inducible factor 2α (HIF-2α) | View |
| None | Renal Cell Carcinoma (RCC) | View |
| None | Kidney Cancer | View |
| None | PT-2977 | View |
| None | PT2977 | View |
| None | MK6482 | View |